ROQ — Roquefort Therapeutics Share News
0.000.00%
FinancialsHighly SpeculativeMicro Cap
- £2.63m
- £2.63m
- £0.00m
REG - Roquefort Theraptcs. - MDK Oncology Antibodies Demonstrate In-Vivo Safety
AnnouncementREG - Roquefort Theraptcs. - Holding(s) in Company
AnnouncementREG - Roquefort Theraptcs. - Appointment of Auditor
AnnouncementREG - Roquefort Theraptcs. - Operations Update
AnnouncementRCS - Roquefort Theraptcs. - Presentation of Midkine Oligonucleotide Program
AnnouncementREG - Roquefort Theraptcs. - Resignation of Auditor
AnnouncementRCS - Roquefort Theraptcs. - Midkine Antibody Program - Festival of Biologics
AnnouncementRCS - Roquefort Theraptcs. - ROQ Presents Study Results at the ESGCT Conference
AnnouncementREG - Roquefort Theraptcs. - Director/PDMR Shareholding
AnnouncementREG - Roquefort Theraptcs. - Director/PDMR Shareholding
AnnouncementREG - Roquefort Theraptcs. - Interim Results to 30 June 2022
AnnouncementRCS - Roquefort Theraptcs. - Investor Presentation
AnnouncementREG - Roquefort Theraptcs. - Board and Management Appointments
AnnouncementREG - Roquefort Theraptcs. - Acquisition Completion, Admission & Voting Rights
AnnouncementREG - Roquefort Theraptcs. - Notice of Admission
AnnouncementREG - Roquefort Theraptcs. - Publication of Prospectus
AnnouncementREG - Roquefort Theraptcs. - Pre-clinical Program & Transaction Update
AnnouncementREG - Roquefort Theraptcs. - Appointment of Joint Broker
AnnouncementREG - Roquefort Theraptcs. - Commencement of Trading on US OTCQB Venture Market
Announcement